Pages that link to "Q46002868"
Jump to navigation
Jump to search
The following pages link to 2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. (Q46002868):
Displaying 50 items.
- Improved targeting of miRNA with antisense oligonucleotides (Q24547511) (← links)
- miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates (Q24647285) (← links)
- Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides (Q24793675) (← links)
- Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain (Q26770355) (← links)
- Epigenetic associations in relation to cardiovascular prevention and therapeutics (Q26771428) (← links)
- Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis (Q26782089) (← links)
- Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy (Q27025832) (← links)
- Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline (Q27694686) (← links)
- Technologies for controlled, local delivery of siRNA (Q28087657) (← links)
- Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation (Q28283087) (← links)
- Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant (Q28369580) (← links)
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice (Q28588849) (← links)
- 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo (Q30048726) (← links)
- Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness (Q30450036) (← links)
- Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. (Q30453773) (← links)
- Triple helix formation and the antigene strategy for sequence-specific control of gene expression (Q30870239) (← links)
- Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry (Q30972411) (← links)
- Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo (Q30977445) (← links)
- Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. (Q31967436) (← links)
- Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon (Q33278100) (← links)
- Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA. (Q33286173) (← links)
- Glioma angiogenesis: Towards novel RNA therapeutics (Q33414996) (← links)
- Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides (Q33607807) (← links)
- Pharmacology of antisense oligonucleotide inhibitors of protein expression (Q33716194) (← links)
- Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination (Q33771816) (← links)
- Oligonucleotide-based strategies to combat polyglutamine diseases (Q33791247) (← links)
- Slow non-specific accumulation of 2'-deoxy and 2'-O-methyl oligonucleotide probes at mitochondria in live cells (Q33871208) (← links)
- Novel mechanisms for antisense-mediated regulation of gene expression (Q33916092) (← links)
- 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation (Q33916133) (← links)
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model (Q34030144) (← links)
- Antisense approaches for the treatment of cancer (Q34063261) (← links)
- Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides (Q34160291) (← links)
- Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy (Q34168139) (← links)
- The clinical potential of microRNAs (Q34220723) (← links)
- Fully modified 2' MOE oligonucleotides redirect polyadenylation (Q34281915) (← links)
- Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs (Q34298362) (← links)
- siRNAs: applications in functional genomics and potential as therapeutics (Q34310668) (← links)
- Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing (Q34333225) (← links)
- Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency (Q34344380) (← links)
- Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? (Q34455538) (← links)
- Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia (Q34499502) (← links)
- Telomerase inhibition, oligonucleotides, and clinical trials (Q34535686) (← links)
- Antisense as a neuroscience tool and therapeutic agent (Q34553851) (← links)
- The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes (Q34645854) (← links)
- Structural characteristics of 2'-O-(2-methoxyethyl)-modified nucleic acids from molecular dynamics simulations (Q34674518) (← links)
- Inhibitory effects of intrathecal p38β antisense oligonucleotide on bone cancer pain in rats (Q34733108) (← links)
- Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. (Q34776352) (← links)
- Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. (Q34994545) (← links)
- U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP (Q35017819) (← links)
- Lowering apolipoprotein CIII delays onset of type 1 diabetes (Q35081529) (← links)